ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.85
-0.26 (-1.29%)
At close: Dec 5, 2025, 4:00 PM EST
19.69
-0.16 (-0.80%)
After-hours: Dec 5, 2025, 7:10 PM EST
ADMA Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 488.56 | 426.45 | 258.22 | 154.08 | 80.94 | 42.22 | Upgrade
|
| Revenue Growth (YoY) | 27.63% | 65.16% | 67.58% | 90.36% | 91.72% | 43.85% | Upgrade
|
| Cost of Revenue | 221.28 | 206.9 | 167.17 | 118.82 | 79.77 | 53.79 | Upgrade
|
| Gross Profit | 267.28 | 219.55 | 91.04 | 35.27 | 1.17 | -11.57 | Upgrade
|
| Selling, General & Admin | 96.37 | 78.37 | 62.59 | 70.3 | 55.19 | 39.22 | Upgrade
|
| Research & Development | 3.78 | 1.81 | 3.3 | 3.61 | 2.85 | 5.91 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.12 | 0.39 | 0.72 | 0.72 | 0.72 | 0.72 | Upgrade
|
| Operating Expenses | 100.27 | 80.57 | 66.61 | 74.63 | 58.75 | 45.84 | Upgrade
|
| Operating Income | 167.02 | 138.98 | 24.43 | -39.37 | -57.57 | -57.41 | Upgrade
|
| Interest Expense | -8.36 | -13.93 | -25.03 | -19.28 | -13.06 | -11.99 | Upgrade
|
| Interest & Investment Income | 1.98 | 2.1 | 1.62 | 0.05 | 0.04 | 0.29 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.28 | -0.19 | -0.29 | -0.64 | -0.25 | -0.13 | Upgrade
|
| EBT Excluding Unusual Items | 160.35 | 126.96 | 0.74 | -59.23 | -70.85 | -69.24 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -7.5 | Upgrade
|
| Asset Writedown | - | - | -2.1 | - | - | - | Upgrade
|
| Other Unusual Items | -4.58 | -1.24 | -26.87 | -6.67 | -0.8 | 0.99 | Upgrade
|
| Pretax Income | 155.77 | 125.71 | -28.24 | -65.9 | -71.65 | -75.75 | Upgrade
|
| Income Tax Expense | -53.67 | -71.96 | - | - | - | - | Upgrade
|
| Net Income | 209.45 | 197.67 | -28.24 | -65.9 | -71.65 | -75.75 | Upgrade
|
| Net Income to Common | 209.45 | 197.67 | -28.24 | -65.9 | -71.65 | -75.75 | Upgrade
|
| Shares Outstanding (Basic) | 238 | 233 | 224 | 198 | 140 | 86 | Upgrade
|
| Shares Outstanding (Diluted) | 246 | 243 | 224 | 198 | 140 | 86 | Upgrade
|
| Shares Change (YoY) | 3.49% | 8.65% | 13.19% | 41.77% | 62.03% | 58.51% | Upgrade
|
| EPS (Basic) | 0.88 | 0.85 | -0.13 | -0.33 | -0.51 | -0.88 | Upgrade
|
| EPS (Diluted) | 0.86 | 0.81 | -0.13 | -0.33 | -0.51 | -0.88 | Upgrade
|
| Free Cash Flow | 40.73 | 110.45 | 4.03 | -73.42 | -125.88 | -114.73 | Upgrade
|
| Free Cash Flow Per Share | 0.17 | 0.45 | 0.02 | -0.37 | -0.90 | -1.33 | Upgrade
|
| Gross Margin | 54.71% | 51.48% | 35.26% | 22.89% | 1.45% | -27.41% | Upgrade
|
| Operating Margin | 34.19% | 32.59% | 9.46% | -25.55% | -71.13% | -135.99% | Upgrade
|
| Profit Margin | 42.87% | 46.35% | -10.94% | -42.77% | -88.52% | -179.41% | Upgrade
|
| Free Cash Flow Margin | 8.34% | 25.90% | 1.56% | -47.65% | -155.52% | -271.74% | Upgrade
|
| EBITDA | 175.01 | 147.03 | 32.76 | -32.25 | -52.08 | -53.47 | Upgrade
|
| EBITDA Margin | 35.82% | 34.48% | 12.69% | -20.93% | -64.34% | -126.65% | Upgrade
|
| D&A For EBITDA | 7.99 | 8.05 | 8.33 | 7.11 | 5.5 | 3.94 | Upgrade
|
| EBIT | 167.02 | 138.98 | 24.43 | -39.37 | -57.57 | -57.41 | Upgrade
|
| EBIT Margin | 34.19% | 32.59% | 9.46% | -25.55% | -71.13% | -135.99% | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 42.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.